U.S. Animal and Plant Health Inspection Service has approved a duration of immunity — or DOI —claim for Boehringer Ingelheim Vetmedica's Ingelvac CircoFLEX of at least four months for porcine circovirus type 2. PCV2 is the primary pathogen for porcine circovirus associated disease.
According to Klaas Okkinga, marketing manager for BIVI, the approved DOI label extension substantiates extensive research that shows Ingelvac CircoFLEX provides long-lasting protection from PCV2. “A vaccine that provides at least four months of PCV2 immunity is a significant benefit to producers in protecting pigs, both early and late, from damage caused by this disease,” says Okkinga.
“Ingelvac CircoFLEX is the only PCV2 vaccine available with proven DOI of this length when administered as a single-dose to pigs 3 weeks of age or older,” Okkinga adds. “Even when administered early, it still protects through the critical grow/finish period, resulting in reduced pig mortality and improved performance.”
For more information on Ingelvac CircoFLEX vaccine for PCV2, as well as the diagnosis and management of PCVAD, contact BIVI, at (800) 325-9167.
For more information, visit: www.bi-vetmedica.com.